Condition: Drug Monitoring · Carcinoma, Non-Small-Cell Lung · Lung Cancer · Sponsor: University Medical Center Groningen
The ADAPT ALEC randomized controlled trial (RCT) is performed in patients with Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC). The RCT will compare the use of Therapeutic Drug Monitoring (TDM) and dose increases if alectinib 35 ng/Ml (arm A) with standard of care (arm B).
This description comes directly from the study's public registry record.
M.B. Muntinghe-Wagenaar, Msc · +31503616161 · adaptalec@umcg.nl
Always discuss trial participation with your own doctor first.
| Gustave Roussy | Villejuif, Val-de-Marne, France | Not Yet Recruiting |
| Radboud University Medical Center | Nijmegen, Gelderland, Netherlands | Recruiting |
| Maastricht University Medical Center + | Maastricht, Limburg, Netherlands | Recruiting |
| The Netherlands Cancer Institute | Amsterdam, North Holland, Netherlands | Recruiting |
| Amsterdam University Medical Center | Amsterdam, North Holland, Netherlands | Recruiting |
| Leiden University Medical Center | Leiden, South Holland, Netherlands | Recruiting |
| Erasmus Medical Center | Rotterdam, South Holland, Netherlands | Recruiting |
| University Medical Center Groningen | Groningen, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05525338